Does ibrutinib cause hair loss?
Hair loss (alopecia) has not been noted as a side effect of ibrutinib (Imbruvica) in the product label. Textural hair changes (softening, straightening or curliness) and nail changes (brittle fingernails and toenails) were reported in a study evaluating ibrutinib use over the long term for treatment of chronic lymphocytic leukemia (CLL).
- In this survey, textural hair changes were reported in 17 out of 66 patients (25.7%) after a median of 9 months after starting treatment for CLL (but ranged from 6 to 12 months). Seven males (16%) and 10 females (43%) reported hair changes in the study.
- Over half of patients reported a negative impact of hair changes on their quality of life.
- On average, textural hair changes were graded 1-2 on a side effect scale, meaning this side effect was considered to be mild to moderate in severity.
Hair straighteners and perming agents used to change hair texture work by changing the disulfide bonds in hair. Ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor, binds to the cysteine residue at the active site of Bruton's tyrosine kinase (BTK) and can change the disulfide bonds between cysteine residues. Whether this cancer mechanism may lead to the observed hair changes is not known.
If you are using ibrutinib in combination with other cancer treatments, those cancer treatments may cause hair loss (alopecia). Ibrutinib can be used in combination with rituximab to treat CLL. Rituximab has been reported to cause hair loss in 13% of patients being treated for pemphigus vulgaris, a skin condition that causes blisters. Hair loss was not reported when rituximab was used in studies to treat CLL.
The most common side effects of ibrutinib (Imbruvica) in adults being treated for B-cell malignancies like CLL include: diarrhea, tiredness, muscle and bone pain, rash, and bruising.
This is not all the information you need to know about ibrutinib (Imbruvica) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Imbruvica information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related questions
References
- Bitar C, Farooqui MZ, Valdez J, et al. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. JAMA Dermatol. 2016 Jun 1;152(6):698-701. doi: 10.1001/jamadermatol.2016.0225.
- Imbruvia (ibrutinib) prescribing information. Janssen Biotech. Horsham, PA, 12/2020. Accessed June 4, 2021 at https://www.imbruvica.com/files/prescribing-information.pdf
Read next
Acalabrutinib vs. ibrutinib: How do they compare?
A 2021 phase III study in the Journal of Clinical Oncology found that while both medications have similar efficacy, acalabrutinib was better tolerated with fewer side effects. Continue reading
How quickly does Imbruvica (ibrutinib) work?
In some people, very good partial clinical responses to Imbruvica may occur within three to six months. Imbruvica is usually given until disease progression or unacceptable toxicity occurs, or in the case of graft vs host disease, recurrence of an underlying malignancy. The average duration of Imbruvica therapy in clinical trials has been around 41 months (range, 2–51 months). Continue reading
What is the success rate of Rituxan (rituximab) in patients with blood cancers?
In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).
Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.
Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading
Related medical questions
- Is Imbruvica a chemotherapy drug?
- Who makes Imbruvica?
- What are the names of the BTK inhibitors?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- How does the drug Rituxan work?
- What is the difference between Truxima and Rituxan?
- Is Venclexta (venetoclax) chemotherapy?
- Does Truxima make you gain weight?
- How do you prepare for a Rituxan infusion?
- What causes infusion reactions to rituximab?
- How effective is Venclexta?
- How long do you take Venclexta for?
- Is Truxima a chemotherapy drug?
- How is Arzerra administered and how long to work?
- Is Zydelig a chemotherapy drug?
- How is Bendeka different to Treanda?
- What is Zydelig used for and how does it work?
- What is Arzerra used for and how does it work?
- How long does it take for Jaypirca to work?
- What is the difference between Rituxan and Rituxan Hycela?
- Who makes Leukeran, and where is it made?
- How is Rituxan Hycela administered?
- What is the success rate of Breyanzi?
- How does Venclexta work?
- What type of drug is Copiktra?
Drug information
Related support groups
- Ibrutinib (10 questions, 14 members)
- Imbruvica (8 questions, 37 members)
- Chronic Lymphocytic Leukemia (CLL) (26 questions, 57 members)
- Lymphoma (17 questions, 44 members)
- Non-Hodgkin's Lymphoma (15 questions, 39 members)
- Mantle Cell Lymphoma (9 questions, 9 members)
- Graft-versus-host disease (4 questions, 4 members)
- Waldenström Macroglobulinemia (1 questions, 6 members)